Australia Infection Control Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Product (Disinfectants, Sterilization (Low-Temperature Sterilization, Heat Sterilization, Contract Sterilization)), By End User Industry (Healthcare, Food And Beverage, Chemical) - Forecasts From 2025 to 2030

Description

Australia Infection Control Market Size:

The Australia Infection Control Market is projected to grow significantly during the forecast period (2025-2030).

The Australia Infection Control Market operates under the dual imperative of managing a high volume of routine surgical and clinical procedures while navigating the structural necessity of mitigating Healthcare Associated Infections (HAIs). This sector, encompassing consumables, equipment, and services, is characterized by rigorous regulatory oversight from the Therapeutic Goods Administration (TGA) and standards set by the Australian Commission on Safety and Quality in Health Care (ACSQHC). The market’s demand profile is fundamentally resilient, supported by a universally accessible healthcare system and a high level of clinical sophistication that prioritizes patient safety. The continued threat of antimicrobial resistance (AMR), a national health priority identified in the Antimicrobial Resistance Strategy, 2020 and beyond, drives significant investment, not only in sterilization and disinfection but also in digital tracking and monitoring systems to ensure compliance and surveillance.

Australia Infection Control Market Analysis

• Growth Drivers

The primary factor propelling market growth is the persistently high incidence of Healthcare Associated Infections (HAIs), which amount to an estimated 170,574 cases annually from the top five common HAIs. This statistic mandates continuous investment in high-efficacy infection control products to reduce patient morbidity, which directly increases demand for advanced sterilization equipment and premium disinfectants. Furthermore, the Australian Commission on Safety and Quality in Health Care (ACSQHC) continually updates its IPC guidelines (latest revision in 2024), emphasizing multimodal, evidence-based strategies and proactive monitoring. This formal regulatory tightening compels all health service organizations to upgrade their practices and procurement, driving demand for new, compliant services and technology solutions. Finally, the country’s high-volume surgical schedule and robust medical device reprocessing requirement necessitate a constant supply of sterilization consumables and maintenance services.

• Challenges and Opportunities

The primary challenge constraining market efficiency is the high dependency on complex global supply chains for specialized sterilization equipment and key chemical raw materials. This dependency exposes the market to international freight volatility and geopolitical risks, creating pricing and supply-continuity headwinds for Australian hospitals. Conversely, a significant opportunity lies in the adoption of digital compliance and surveillance systems. The recent ACSQHC guideline revisions emphasize continuous improvement and proactive monitoring, driving demand for technology solutions like AI-powered electronic infection tracking systems and Hand Hygiene Compliance Systems (HHCS). These tools automate compliance monitoring and identify outbreaks early, offering a high-value service opportunity for vendors that integrate software platforms with traditional infection control products.

• Raw Material and Pricing Analysis

The infection control market, being a physical product sector, is highly sensitive to raw material dynamics, specifically for disinfectants and sterilization consumables. Key chemical components, such as chlorhexidine, isopropyl alcohol (IPA), and specialized polymers for PPE and sterilization wraps, are largely sourced from global production centers, mainly in Asia. Pricing is directly influenced by the Australian Dollar’s exchange rate against the USD and global supply chain stability. For instance, TGA actions, such as the Class I recall of antiseptic products in early 2025 due to contamination, immediately shifted demand toward alternative or higher-priced, TGA-approved formulations (e.g., specific 3M SoluPrep products), creating a temporary but sharp divergence in pricing and raw material preference, prioritizing quality and verifiable purity over cost.

• Supply Chain Analysis

The infection control supply chain is inherently complex, defined by the manufacturing hubs for physical products. Sterilization equipment (e.g., autoclaves, endoscope reprocessors) is primarily manufactured in the US and Europe (e.g., STERIS, Getinge), requiring specialized, high-cost sea or air freight to Australia. Disinfectants and PPE (consumables) are largely manufactured in high-volume, low-cost facilities in Asian countries, necessitating robust quality control checks upon Australian arrival to meet TGA standards. Logistical complexity in the final mile involves navigating Australia's sparse population density and vast geographical area to supply remote health facilities, often requiring highly reliable, temperature-controlled distribution, particularly for sensitive chemicals and biological indicators. This system is heavily reliant on a small number of specialized medical distributors for final delivery and service support.

• Government Regulations

Australia Infection Control Market Segment Analysis

• By Product: Disinfectant

The Disinfectant segment is characterized by evolving demand influenced heavily by post-pandemic awareness and regulatory scrutiny. The core demand driver is the escalating regulatory pressure to mitigate environmental contamination. The ACSQHC’s IPC guidelines now place explicit emphasis on environmental cleaning and the reprocessing of reusable medical devices (RMDs), which necessitates the continuous, high-volume use of specialized, hospital-grade surface and instrument disinfectants. This demand is increasingly moving away from simple alcohol-based formulations toward advanced, TGA-approved chemistries that demonstrate efficacy against high-threat pathogens like Clostridioides difficile and Multi-drug Resistant Organisms (MDROs), which are rising concerns in Australian hospitals. The TGA’s assertive regulatory actions against contaminated products further concentrates demand on market-leading brands that can guarantee product integrity and supply chain reliability.

• By End User Industry: Healthcare

The Healthcare segment represents the dominant end-user, with demand driven by the sheer scale and complexity of the Australian health system. The core demand driver is the critical national priority of minimizing Healthcare Associated Infections (HAIs), which are tracked and reported nationally. The demand is structurally resilient, anchored by the continuous high-volume demand from public and private hospitals, aged care facilities, and dental clinics for sterilization and cleaning products. The establishment of the interim Australian Centre for Disease Control (CDC) in January 2024 underscores a formalized, whole-of-government approach to communicable disease prevention, which will drive significant public procurement demand for everything from basic hand hygiene solutions to complex, high-level disinfection protocols to ensure national preparedness against future infectious threats.

Australia Infection Control Market Competitive Environment and Analysis

The Australia Infection Control Market features intense competition between global industry leaders offering high-technology equipment and chemical giants providing essential consumables, often through local partnerships and distribution channels.

Australia Infection Control Market Competitive Landscape

The market is dominated by major multinational corporations with established global portfolios, including STERIS Plc., 3M Company, Getinge AB, and Ecolab Inc., who maintain strong local distribution networks.

• STERIS Plc.: STERIS’s strategic positioning focuses on commanding the high-technology, capital-intensive Sterilization Equipment segment, including washers, low-temperature sterilizers, and endoscope reprocessors, which are critical for hospital Central Sterile Supply Departments (CSSD). The company leverages its global scale and patented technologies to provide integrated solutions that meet the stringent Australian Standard AS 5369:2023 for the reprocessing of reusable medical devices, creating high customer lock-in through equipment maintenance and specialized consumables sales.
• 3M Company: 3M’s strategic positioning spans both the Consumables and Sterilization segments, utilizing its diverse product lines to secure a broad market footprint. The company is a key supplier of Personal Protective Equipment (PPE), surgical supplies, and chemical indicators for sterilization monitoring. 3M's strength in Australia was demonstrated during the late 2024/early 2025 antiseptic recalls, where its 3M SoluPrep products were explicitly listed as verified alternatives, underscoring its trusted reputation and regulatory compliance in the Australian Healthcare sector.
• Ecolab Inc.: Ecolab’s strategy centers on comprehensive Environmental Hygiene Services and Disinfectant Solutions across the entire healthcare ecosystem, including hospitals and aged care. The company focuses on a total system approach, integrating chemistry with digital services and training to improve compliance. Its recent local product launches, such as the Pay As You Go Endo Bundle in November 2025 and new bedpan washers in February 2025, show a proactive approach to capturing market share in the critical endoscope reprocessing and environmental hygiene segments by offering flexible acquisition models.

Australia Infection Control Market Developments

• November 2025: Ecolab Healthcare ANZ Launches Pay As You Go Endo Bundle

Ecolab Healthcare ANZ announced the launch of the Pay As You Go Endo Bundle, an innovative product acquisition and service model for endoscope reprocessing. This development represents a product launch and capacity addition in service delivery, directly addressing Australian hospitals’ financial and operational constraints by offering a flexible, bundled approach to specialized equipment and consumables, thereby enhancing customer affordability and market access for Ecolab’s endoscope infection control portfolio.

Australia Infection Control Market Segmentation:

By Type of Offering

• Solutions
• Services
• Equipment

By Product

• Disinfectant
• Sterilization
• Low-temperature Sterilization
  • Heat Sterilization
  • Contract Sterilization
  • Others

By End User Industry

• Healthcare
• Food and Beverage
• Chemical

Table Of Contents

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. Technological Outlook

5. Australia Infection Control MARKET BY type of offering

5.1. Introduction

5.2. Solutions

5.3. Services

5.4. Equipment

6. Australia Infection Control MARKET BY product

6.1. Introduction

6.2. Disinfectant

6.3. Sterilization

6.3.1. Low-temperature Sterilization

6.3.2. Heat Sterilization

6.3.3. Contract Sterilization

6.3.4. Others

7. Australia Infection Control MARKET BY end-user industry

7.1. Introduction

7.2. Healthcare

7.3. Food and Beverage

7.4. Chemical

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. 3M

9.2. Getinge AB

9.3. B. Braun Melsungen AG

9.4. STERIS plc

9.5. Ecolab Inc.

9.6. Reckitt Benckiser Group plc

9.7. Belimed AG

9.8. Advanced Sterilization Products (ASP)

9.9. EBOS Healthcare

9.10. MMM Group

10. APPENDIX

10.1. Currency

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key benefits for the stakeholders

10.5. Research Methodology

10.6. Abbreviations

LIST OF FIGURES

LIST OF TABLES

Companies Profiled

3M

Getinge AB

B. Braun Melsungen AG

STERIS plc

Ecolab Inc.

Reckitt Benckiser Group plc

Belimed AG

Advanced Sterilization Products (ASP)

EBOS Healthcare

MMM Group 

Related Reports